Health and Healthcare
Crushing Blow for Gilead, Billions of Dollars (GILD)
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) is being crushed after a disappointing result in its Hepatitis C treatment after reporting that a majority of hepatitis C genotype-1 patients who had a previous null response to an interferon regimen experienced viral relapse within four weeks of completing 12 weeks of treatment.
This result was in patients who were enrolled in the ongoing ELECTRON study with Gilead’s GS-7977 plus ribavirin. In this arm of the study, patients were randomized and the data is available for 8 out of the 10 patients at this time. Six of these eight have experienced a viral relapse and the two patients which have not relapsed have only reached two weeks after the point of measurement in the treatment.
Gilead shares are getting crushed in the pre-market. After closing at $54.81, the pre-market level is down 19.2% at $44.28 and the volume is active considering over two hours remain until the open. Gilead’s market value was $41.3 billion before this move, and if the pre-market drop of 19.2% holds up then nearly $8 billion in equity value will have been destroyed.
JON C. OGG
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.